Post-earnings recap
Reported
Wed, Nov 1, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 1.9% following the earnings report, likely due to the lack of revenue details and forward guidance. Investors may be cautious as they await more information on the company's future performance and pipeline advancements.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.13 | N/A | +72.33% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the quarter's performance, highlighting ongoing efforts in product development. They emphasized a commitment to their strategic goals.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.